BeyondSpring Announces Plinabulin and ADC Combination Poster Presentation at AACR Annual Meeting 2026

robot
Abstract generation in progress

BeyondSpring Inc. (NASDAQ: BYSI), a clinical-stage biopharmaceutical company, announced that it will present a poster on Plinabulin and ADC combination at the 2026 AACR Annual Meeting. The presentation, titled “Plinabulin Boosts Antitumor Efficacy of Topoisomerase Inhibitor-based Antibody-drug Conjugates Without or With Immune Checkpoint Inhibitor,” will detail how Plinabulin enhances the effectiveness of antibody-drug conjugates. This aims to highlight its potential in improving cancer treatment outcomes, particularly in restoring tumor sensitivity to checkpoint inhibitors.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments